Last updated on July 2019

Study Evaluating Safety Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer

Brief description of study

A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer

Detailed Study Description

This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 administered as a short term intravenous (IV) infusion in subjects with small cell lung cancer. AMG 757 is a Half Life Extended (HLE) Bispecific T cell engager (BiTE) targeting delta-like protein 3 (DLL3)

Clinical Study Identifier: NCT03319940

Find a site near you

Start Over

Research Site

Kashiwa-shi, Japan
  Connect »